"Growth hormone secretagogue" describes an outcome, not a mechanism, and the compounds grouped under it act at two entirely different receptors. Reading them as one class is the most common source of confusion in this part of a catalogue.
| Group | Receptor | Compounds here | Origin |
|---|---|---|---|
| GHRH analogues | GHRH receptor (GHRHR) | Sermorelin, Tesamorelin, CJC-1295 (no DAC) | Modelled on native GHRH |
| Ghrelin receptor agonists | GHS-R1a | Ipamorelin, GHRP-6 | Discovered independently of GHRH |
These are unrelated receptors with different signalling. A compound acting at one is not a variant of a compound acting at the other, however similar the label sounds.
The GHRH analogue group
Native GHRH is a 44-residue peptide whose biologically active portion is the first 29 residues. Everything in this group is a modification of that fragment, and what distinguishes them is which stability problem the modification solves.
- Sermorelin is GHRH(1-29) essentially as nature wrote it — the active fragment, unmodified. It is the reference point the others are departures from, and its short persistence is the problem they address.
- Tesamorelin is GHRH(1-44) carrying a stabilising modification at the N-terminus. The N-terminal region is where dipeptidyl peptidase attacks, so protecting it addresses the primary degradation route directly.
- CJC-1295 without DAC — more precisely, modified GRF(1-29) — carries amino-acid substitutions that resist the same enzymatic attack, without the drug-affinity complex that gives the "with DAC" version its much longer persistence.
Why does "no DAC" matter so much in the name?
Because the two versions are genuinely different molecules with different research profiles, and the naming is unhelpfully similar. The drug-affinity complex is a maleimide group that binds covalently to circulating albumin, which is what extends persistence dramatically — a different mechanism from the reversible albumin binding acylated peptides use. Remove it and you have a peptide with substitution-based resistance only. Published work on one does not transfer to the other, and "CJC-1295" used without specifying which is ambiguous to the point of being unusable in a methods section.
The ghrelin receptor group
GHS-R1a was characterised before its natural ligand was known — the receptor was found by working backwards from synthetic compounds that stimulated growth hormone release, and ghrelin was identified as the endogenous ligand afterwards. That history is why this group exists separately from the GHRH analogues rather than as a variation on them.
Within the group, selectivity is the main axis of difference. Ipamorelin was introduced in 1998 and is described in the literature as the first selective compound of its type, with a profile reported as more confined than earlier peptides such as GHRP-6 — which is the property most of the subsequent literature is interested in.
Why are the two groups so often combined?
Because they act at different receptors, which means they can be studied together without the two competing for the same binding site. CJC-1295 (no DAC) + Ipamorelin and CJC-1295 (no DAC) + GHRP-6 pair one from each group for exactly that reason. Whether co-formulation is the right way to study that is a separate question — a blend fixes the ratio, which is useful when the ratio is settled and limiting when it is the variable.
Does a longer half-life make a compound better for research?
Not inherently — it makes it different, and often harder to study. A short-acting compound gives a clean, time-resolved signal; a long-acting one integrates over a period and makes pulsatility impossible to observe. If the research question concerns the pattern of release rather than its total magnitude, the stabilised analogue is the wrong tool. Persistence is a design parameter to match to the question, not a quality ranking. Downstream of this axis, IGF-1 LR3 was engineered for availability rather than potency — a related but distinct design choice, and one that is misread the same way.
What should a methods section record?
The exact compound including any modification — "modified GRF(1-29), without DAC" rather than "CJC-1295" — plus lot, supplier, purity and net peptide content — and, for the GHRH analogues, the length and N-terminal modification, since sermorelin and tesamorelin differ in duration by orders of magnitude on those alone. For this group in particular, the compound name alone is not sufficient to identify the material, and a reader cannot evaluate the work without knowing which molecule was used.
Why the distinction keeps getting lost
Three reasons, and they compound. The compounds produce an overlapping readout, so a study measuring only that readout cannot distinguish them by result. The category name describes the readout rather than the mechanism, so the label itself invites the conflation. And secondary sources — supplier copy, summaries, forum posts — frequently list them together without noting the receptor difference, so the error propagates faster than the correction.
The cost is not academic. A literature search treating them as one class returns a mixture of papers about two different receptors, and conclusions drawn across that mixture are unsound.
What does GHRP-6 add that ipamorelin does not?
Breadth, which is sometimes the point. GHRP-6 is an earlier compound and is described in the literature as less confined in its activity than ipamorelin. Where a study is asking whether the ghrelin receptor pathway is involved at all, a broader compound is a reasonable probe. Where it is asking what that receptor specifically does, the more selective compound is the better instrument. Neither is a superior molecule in the abstract.
Do the two groups interact when studied together?
They act at separate receptors, so they do not compete for a binding site — which is the reason they are studied in combination. Whether their downstream signalling converges, and how, is an experimental question rather than a settled one, and it is precisely what a combination study is designed to probe. That it can be asked at all depends on the receptors being distinct.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
